# US 2026/0285875 A1 · Inhibitors of parg

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0285875 A1
- Document ID: US20260285875A1
- Status: Published application
- Kind: A1
- Application number: 19/671,000
- Filed: 2026-05-07
- Published: 2026-09-24
- Earliest claimed: 2023-11-22
- Assignees: 858 Therapeutics, Inc.
- Applicants: 858 Therapeutics, Inc.
- Inventors: Shyama HERATH; James M. VEAL; Jeffrey A. STAFFORD; Taylor ALEXANDER; Grant SEILER; Riley MILLS; Christopher MCBRIDE; Donald S. KARANEWSKY
- Web page: https://patentgrep.com/patent/US20260285875A1

## CPC

- C07D 498/04: Ortho-condensed systems
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 31/433: Thidiazoles
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5365: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/537: spiro-condensed or forming part of bridged ring systems
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5395: having two or more nitrogen atoms in the same ring, e.g. oxadiazines
- C07B 59/002: {Heterocyclic compounds}
- C07D 471/14: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 487/10: Spiro-condensed systems
- C07D 487/14: Ortho-condensed systems
- C07D 491/147: the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
- C07D 495/14: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 35/00: Antineoplastic agents
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are inhibitors of PARG, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the PARG inhibitory compounds for the treatment of disease.

## Claims

### Claim 1

A compound, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, having the structure of Formula (I):
wherein,
B is a bond, C═O, or CN—OR9;
W is a bond, —O—, or C(R10)(R11), or NR7;
X is —S—, or —*Y═C(A)—; wherein the * indicates point of attachment to C—SO2 group;
Y is N, C—H, C—F, C—O(optionally substituted C1-C6 alkyl), C—NH2, C—NH(optionally substituted C1-C6 alkyl), C—N(optionally substituted C1-C6 alkyl)2, C—SH, C—S(optionally substituted C1-C6 alkyl), C—NH(optionally substituted (heteroaryl)alkylene), —C—NH(optionally substituted (heteroaryl)alkynylene);
A is selected from the group consisting of hydrogen, halo, —OH, —CN, optionally substituted C1-C6 alkoxy, —N(R7)2, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C7 carbocyclyl, optionally substituted (carbocyclyl)alkylene, optionally substituted (carbocyclyl)alkynylene, optionally substituted heterocyclyl, optionally substituted (heterocyclyl)alkylene, optionally substituted heteroaryl, and optionally substituted aryl;
R1 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted (cycloalkyl)alkylene, optionally substituted (aryl)alkylene, optionally substituted (heterocyclyl)alkylene, optionally substituted (heteroaryl)alkylene, optionally substituted (heteroaryl)alkynylene, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3-C7 carbocyclyl, and optionally substituted heterocyclyl;
R2 and R3 are independently selected from the group consisting of hydrogen, halo, —OH, —CN, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted (cycloalkyl)alkylene, optionally substituted (heterocyclyl)alkylene, optionally substituted (aryl)alkylene, optionally substituted (heteroaryl)alkylene, optionally substituted (cycloalkyl)alkenylene, optionally substituted (heterocyclyl)alkenylene, optionally substituted (aryl)alkenylene, optionally substituted (heteroaryl)alkenylene, optionally substituted (cycloalkyl)alkynylene, optionally substituted (heterocyclyl)alkynylene, optionally substituted (heteroaryl)alkynylene, optionally substituted (aryl)alkynylene, optionally substituted (cycloalkyl)-O-alkylene, optionally substituted (heterocyclyl)-O-alkylene, optionally substituted (aryl)-O-alkylene, optionally substituted (heteroaryl)-O-alkylene, optionally substituted (cycloalkyl)-NR7-alkylene, optionally substituted (heterocyclyl)-NR7-alkylene, optionally substituted (aryl)-NR7-alkylene, optionally substituted (heteroaryl)-NR7-alkylene, optionally substituted (alkyl)-O-alkylene, optionally substituted (alkyl)-NR7-alkylene, optionally substituted (alkyl)-O-alkynylene, and optionally substituted (alkyl)-NR7-alkynylene; or
optionally, R2 and R3 combine to form an optionally substituted carbocyclic or heterocyclic ring;
R4, R5, R10, and R11 are independently selected from the group consisting of hydrogen, halo, —OH, —CN, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkylene, optionally substituted (cycloalkyl)alkynylene, optionally substituted heterocyclyl, optionally substituted (heterocyclyl)alkylene, optionally substituted heteroaryl, and optionally substituted aryl;
or optionally, R4 and R5 combine to form an optionally substituted carbocyclic or heterocyclic ring;
or optionally, R3 and R4 combine to form an optionally substituted carbocyclic or heterocyclic ring;
R6 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, or an optionally substituted 1,1′-bi(cyclopropan)-1-yl;
each R7 is independently hydrogen or an optionally substituted C1-C6 alkyl; and
each R9 is independently hydrogen or an optionally substituted C1-C6 alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein X is -S-.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, having the structure of Formula (II):

### Claim 4 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein W is a bond.

### Claim 5 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein W is O.

### Claim 6 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein W is CR10R11.

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, having the structure of Formula (III):

### Claim 8 (depends on 7)

The compound of claim 7, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein W is a bond.

### Claim 9 (depends on 7)

The compound of claim 7, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein W is O.

### Claim 10 (depends on 7)

The compound of claim 7, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein W is CR10R11.

### Claim 11 (depends on 1)

The compound of any one of claims 1, or 3-10, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein Y is N.

### Claim 12 (depends on 1)

The compound of any one of claims 1, or 3-10, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein Y is C—H.

### Claim 13 (depends on 1)

The compound of any one of claims 1, or 3-10, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein Y is C—F.

### Claim 14 (depends on 1)

The compound of any one of claims 1, or 3-13, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein A is hydrogen.

### Claim 15 (depends on 1)

The compound of any one of claims 1, or 3-13, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein A is halo or —CN.

### Claim 16 (depends on 1)

The compound of any one of claims 1, or 3-13, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein A is optionally substituted C1-C6 alkoxy or -N(R7)2.

### Claim 17 (depends on 1)

The compound of any one of claims 1, or 3-13, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein A is selected from the group consisting optionally substituted C1-C6 alkyl, optionally substituted C3-C7 carbocyclyl, and optionally substituted (carbocyclyl)alkylene.

### Claim 18 (depends on 1)

The compound of any one of claims 1, or 3-13, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein A is optionally substituted heterocyclyl or optionally substituted (heterocyclyl)alkylene.

### Claim 19 (depends on 1)

The compound of any one of claims 1, or 3-13, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein A is selected from optionally substituted heteroaryl or optionally substituted aryl.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 1-19, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R1 is optionally substituted alkyl.

### Claim 21 (depends on 20)

The compound of claim 20, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R1 is optionally substituted C1-C4 alkyl.

### Claim 22 (depends on 20)

The compound of claim 20, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R1 is optionally substituted C1-C4 alkyl and is substituted with at least one substituent selected from —CN, —OR9, halo, oxo, —N(R9)2, or —CON(R9)2; wherein each R9 is independently hydrogen, or optionally substituted C1-C4 alkyl.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 1-19, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R1 is optionally substituted (heteroaryl)alkylene.

### Claim 24 (depends on 23)

The compound of claim 23, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein the optionally substituted heteroaryl is selected from a 5- or a 6-membered heteroaryl.

### Claim 25 (depends on 24)

The compound of claim 24, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein the heteroaryl is selected from a 5-membered nitrogen-containing heteroaryl.

### Claim 26 (depends on 25)

The compound of claim 25, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein the optionally substituted 5-membered nitrogen-containing heteroaryl is selected from optionally substituted thiazole, optionally substituted oxazole, optionally substituted imidazole, optionally substituted pyrazole, optionally substituted isoxazole, optionally substituted pyrrole, optionally substituted oxadiazole, optionally substituted triazole, optionally substituted thiadiazole, or optionally substituted isothiazole or optionally substituted isoxazole.

### Claim 27 (depends on 25)

The compound of claim 25, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein the optionally substituted 5-membered nitrogen-containing heteroaryl is selected from optionally substituted pyrazole or optionally substituted isoxazole.

### Claim 28 (depends on 24)

The compound of claim 24, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein the heteroaryl is a 6-membered nitrogen-containing heteroaryl.

### Claim 29 (depends on 28)

The compound of claim 28, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein the 6-membered nitrogen-containing heteroaryl is an optionally substituted pyridine or optionally substituted pyrazine.

### Claim 30 (depends on 23, 24, 25, 26, 27, 28, 29)

The compound of any one of claims 23-29, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R1 is optionally substituted heteroaralkyl and the alkylene is an optionally substituted C1-C4 alkylene.

### Claim 31 (depends on 30)

The compound of claim 30, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein the optionally substituted C1-C4 alkylene is a —CH2-.

### Claim 32 (depends on 30)

The compound of claim 30, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein the optionally substituted C1-C4 alkylene is a —CD2-.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 1-19, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R1 is optionally substituted (aryl)alkylene.

### Claim 34 (depends on 33)

The compound of claim 33, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein the optionally substituted (aryl)alkylene comprises an optionally substituted phenyl.

### Claim 35 (depends on 33, 34)

The compound of claim 33 or 34, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein the optionally substituted (aryl)alkylene comprises an optionally substituted C1-C4 alkylene.

### Claim 36 (depends on 35)

The compound of claim 35, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein the optionally substituted C1-C4 alkylene is a —CH2— or —CD2-.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 1-19, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R1 is an optionally substituted C4-C7 (carbocyclyl)alkylene.

### Claim 38 (depends on 37)

The compound of claim 37, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein the optionally substituted (carbocyclyl)alkylene is an optionally substituted (cyclopropyl)methylene.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 1-19, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R1 is an optionally substituted (heterocyclyl)alkylene.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 1-19, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R1 is

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The compound of any one of claims 1-40, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R4 is hydrogen or methyl.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The compound of any one of claims 1-41, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R5 is hydrogen or methyl.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The compound of any one of claims 1-42, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R3 is hydrogen or methyl.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The compound of any one of claims 1-43, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R2 is hydrogen.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The compound of any one of claims 1-43, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R2 is not hydrogen.

### Claim 46 (depends on 45)

The compound of claim 45, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R2 is an optionally substituted (heteroaryl)alkynylene.

### Claim 47 (depends on 46)

The compound of claim 46, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein the optionally substituted (heteroaryl)alkynyl is selected from:

### Claim 48 (depends on 45)

The compound of claim 45, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R2 is an optionally substituted (aryl)alkynylene.

### Claim 49 (depends on 46)

The compound of claim 46, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein the optionally substituted (aryl)alkynylene is —C—C≡C6H5.

### Claim 50 (depends on 45)

The compound of claim 45, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R2 is an optionally substituted (aryl)alkenylene.

### Claim 51 (depends on 48)

The compound of claim 48, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein the optionally substituted (aryl)alkenylene is —CH═CH—C6H5.

### Claim 52 (depends on 45)

The compound of claim 45, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R2 is an optionally substituted (aryloxy)alkylene.

### Claim 53 (depends on 52)

The compound of claim 52, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein the optionally substituted (aryloxy)alkylene is
wherein R is selected from halo, —OH, —CN, optionally substituted C1-C6 alkoxy, or optionally substituted C1-C6 alkyl.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The compound of any one of claims 1-43, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R2 is optionally substituted alkynyl.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The compound of any one of claims 1-43, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R2 is optionally substituted C2-C4 alkynyl.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The compound of any one of claims 1-43, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R2 is —C≡C—H.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound of any one of claims 1-56, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R6 is optionally substituted C3-C5 cycloalkyl.

### Claim 58 (depends on 57)

The compound of claim 57, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein the optionally substituted cycloalkyl is:
wherein R8 is selected from the group consisting of hydrogen, —CH3, —CH2F, —CHF2, —CF3, —CN, cyclopropyl, —CH2CH3, —CH(CH3)2, and —C(CH3)3.

### Claim 59 (depends on 1, 2)

The compound of any one of claims 1 or 2, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein B is CN—OR9.

### Claim 60 (depends on 59)

The compound of claim 59, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R9 is H.

### Claim 61 (depends on 59)

The compound of claim 59, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, wherein R9 is optionally substituted C1-C3 alkyl.

### Claim 62

A compound, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, described in Table 1.

### Claim 63

A compound, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, as described in Table 2.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, as described in any one of claims 1-63, and a pharmaceutically acceptable excipient.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A method of preparing a pharmaceutical composition comprising mixing a compound, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, as described in any one of claims 1-63, and a pharmaceutically acceptable carrier.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A compound of any one of claims 1-63, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, for use in a method of treatment of the human or animal body.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A method of treating cancer in a patient in need thereof, comprising administering to the patient a compound as described in any one of claims 1-63, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A method of treating cancer in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound as described in any one of claims 1-63, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, and a pharmaceutically acceptable excipient.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A method of inhibiting a PARG enzyme comprising contacting the enzyme with a compound of any one of claims 1-63, wherein the PARG enzyme is contacted in an in vitro setting.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A method of inhibiting a PARG enzyme comprising contacting the enzyme with a compound of any one of claims 1-63, wherein the PARG enzyme is contacted in an in vivo setting.
